15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial

Authors :: Hernan Valdez
Linda Stein Gold
Thomas Bieber
David A. Williams
Pinaki Biswas
Svitlana Tatulych
Gil Yosipovitch
Shawn G. Kwatra
Michael C. Cameron
Chudy I. Nduaka
Source :: Journal of the American Academy of Dermatology. 83:AB41
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Moderate to severe
medicine.medical_specialty
Quality of life
business.industry
Medicine
Phases of clinical research
In patient
Dermatology
Atopic dermatitis
business
medicine.disease
Eczema Area and Severity Index

Tools